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Summary
 
Fas is an apoptosis-inducing surface receptor involved in controlling tissue homeostasis and
function at multiple sites. Here we show that 
 
b
 
 cells from the pancreata of newly diagnosed in-
sulin-dependent diabetes mellitus (IDDM) patients express Fas and show extensive apoptosis
among those cells located in proximity to Fas ligand–expressing T lymphocytes infiltrating the
IDDM islets. Normal human pancreatic 
 
b
 
 cells that do not constitutively express Fas, become
strongly Fas positive after interleuken (IL)-1
 
b
 
 exposure, and are then susceptible to Fas-medi-
ated apoptosis. N
 
G
 
-monomethyl-
 
l
 
-arginine, an inhibitor of nitric oxide (NO) synthase, prevents
IL-1
 
b
 
–induced Fas expression, whereas the NO donors sodium nitroprusside and nitric oxide
releasing compound (NOC)-18, induce functional Fas expression in normal pancreatic 
 
b
 
 cells.
These findings suggest that NO-mediated upregulation of Fas contributes to pancreatic 
 
b
 
 cell
damage in IDDM.
 
T
 
he interaction of Fas (CD95/Apo-1) with its ligand
promotes the deletion of potentially harmful, dam-
aged, or unnecessary cells during the immune response.
This interaction also regulates tissue remodelling and ho-
meostasis. Impaired Fas-induced apoptosis results in abnor-
mal cell proliferation and accumulation, whereas inappro-
priate expression or excessive Fas activity causes tissue
damage (1–3).
Insulin-dependent diabetes mellitus (IDDM)
 
1
 
 is a T cell–
mediated autoimmune disease resulting from a selective de-
struction of pancreatic 
 
b
 
 cells (4). Two complementary
lytic pathways mediate T cell cytotoxicity: the exocytosis
of perforin-containing granules on cognate target cells, and
the engagement of Fas on cognate or neighboring target
cells by membrane-bound or released Fas ligand (FasL; 5, 6).
Normal pancreatic 
 
b
 
 cells do not express Fas (7). How-
ever, we have recently shown that the exposure of human
 
b
 
 cells to IL-1
 
b
 
 induces Fas expression on these cells, sug-
gesting the existence of an additional pathway that pro-
motes 
 
b
 
 cell destruction (8). The possible role of FasL-
based cytotoxicity in the pathogenesis of autoimmune dia-
betes is suggested by recent findings showing protection
from both spontaneous and T cell–transferred diabetes in
Fas negative NOD
 
lpr/lpr
 
 mice (9). IL-1
 
b
 
 has been reported
to be abundantly present during the insulitis process and se-
lectively toxic for pancreatic 
 
b
 
 cells, as its secretion by acti-
vated macrophages induces transcription and translation of
inducible nitric oxide synthase (iNOS) and nitric oxide
(NO) production (10, 11). During the insulitis process,
iNOS is highly expressed in 
 
b
 
 cells and islet-infiltrating
macrophages (12). Although IL-1
 
b
 
–mediated NO produc-
tion may result in 
 
b
 
 cell damage, and islet-infiltrating mac-
rophages are a major source of NO, it seems unlikely that
this direct cytotoxic effect of NO is responsible for massive
and selective 
 
b
 
 cell destruction (13). We therefore studied
the requirement for functional Fas expression in pancreatic
 
b
 
 cells, and investigated the possible involvement of Fas
and FasL in the pathogenesis of human IDDM.
 
Materials and Methods
 
Subjects.
 
The IDDM pancreata were from two boys (ages 12 and
11), who died in 1992 (patient No. 1) and 1993 (patient No. 2),
respectively, after a diagnosis of type I diabetes mellitus compli-
 
1
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cated by diabetic ketoacidosis (14). Despite appropriate treatment
based on fluid rehydration combined with insulin infusion ther-
apy, both children developed severe brain edema with cerebellar
tonsillar herniation. Upon admission to Children’s Hospital of
Pittsburgh (Pittsburgh, PA), they were found to be brain dead.
After obtaining an informed consent from the parents, the tail,
body, and part of the head of the pancreas were obtained at au-
topsy. In both cases, molecular HLA typing revealed heterozy-
gosity at both DQA1 (i.e., patient No. 1: 
 
*
 
0501, 
 
*
 
0301; and pa-
tient No. 2: 
 
*
 
0101, 
 
*
 
0501) and DQB1 (i.e., patient No. 1: 
 
*
 
0301,
 
*
 
0302; and patient No. 2: 
 
*
 
0201, 
 
*
 
0501) loci. Thus, both patients
had the possibility of forming “diabetogenic” (
 
a
 
Arg-52 and
 
b
 
-non-Asp57) DQ heterodimers (15). Islet cell antibodies were
 
.
 
20 Juvenile Diabetes Foundation (JDF) units in the serum of
patient No. 1, and 
 
,
 
20 in the serum of patient No. 2 (14). 10
normal human pancreas (NHP) specimens were provided by the
Consorzio Centro Sud Trapianti (Palermo, Italy) and the Thomas
E. Starzl Transplantation Center (Pittsburgh, PA) under their re-
spective Institutional Review Board approvals. They were ob-
tained from three female and seven male nondiabetic cadaveric do-
nors (mean age was 25 yr old).
 
Flow Cytometry Analysis of Islet Cells.
 
Pancreatic islets were iso-
lated by the intraductal pancreatic distension method as previ-
ously described (8). Single cell suspensions were obtained by dis-
sociating islets with 3 mM EGTA, 20 mg/ml BSA, 2.8 mM
glucose, and 0.83 
 
m
 
g/ml trypsin (8). Human IFN-
 
g
 
 (specific
activity of 10
 
6
 
 U/mg; Sigma Chemical Co., St. Louis, MO),
TNF-
 
a
 
 (specific activity of 
 
.
 
2 
 
3
 
 10
 
7
 
 U/mg; Boehringer Mann-
heim, Indianapolis, IN), IL-1
 
b
 
 (specific activity of 
 
z
 
5 
 
3
 
 10
 
8
 
 U/
mg; Genzyme, Cambridge, MA), sodium nitroprusside (SNP),
N
 
G
 
-monomethinyl-
 
l
 
-arginine (L-NMMA), and N
 
G
 
-monomethyl-
 
d
 
-arginine (D-NMMA; Sigma Chemical Co.), and NO releasing
compound (Z)-1-[2-(2-aminoethyl)-(N)-(2-ammonioethyl)-
ammo]diazen-1-ium-1,2-diolate] (NOC-18), 
 
l
 
-arginine, and
 
d
 
-arginine (Alexis Corp., Laufelfingen, Switzerland) were added
to the cultures at time 0. Cells were maintained in culture for 72 h
and harvested for evaluation of Fas expression at different time
points. Islet cells were first permeabilized in a fixative solution
containing 0.25% paraformaldehyde and 0.2% Tween 20 for the
labeling with anti-insulin mAb (IgG2a; Novo Nordisk, Bags-
vaerd, Denmark), revealed by an FITC-conjugated goat anti–
mouse Ig antibody. Cells were then incubated for 10 min with
6% normal mouse serum, treated with phycoerythrin-conjugated
anti-CD95 (DX2, IgG1; PharMingen, San Diego, CA), washed
twice in cold PBS/azide, and resuspended at 10
 
6
 
 cells/ml for
cytofluorometric analysis. An isotype-matched antibody was used
as a negative control. Relative fluorescent intensities of individual
cells were analyzed using a FACScan
 
Ò
 
 flow cytometer (Becton
Dickinson, Mountain View, CA).
 
Apoptosis Detection of Islet Cells.
 
After a 24-h culture in the
presence of 50 U/ml IL-1
 
b
 
, 0.5 mM SNP, or IL-1
 
b
 
 plus L-NMMA,
dispersed islet cells were incubated with an isotype-matched con-
trol mAb or with 200 ng/ml of anti-Fas mAb (IgM, clone CH-11;
Upstate Biotechnology Incorporated, New York, NY), or 10
 
m
 
g/ml of anti-Fas–blocking mAb (IgG1, ZB4; Kamiya Biomedi-
cal Company, Tukwila, WA) for a total of 48 h. The percentage
of cells undergoing apoptosis was measured by hypotonic fluoro-
chrome solution staining (50 
 
m
 
g/ml propidium iodide in 0.1%
sodium citrate plus 0.1% Triton X-100; Sigma Chemical Co.)
detected with a FACScan
 
Ò
 
 flow cytometer. Cell recovery was
determined by evaluating the number of surviving insulin or glu-
cagon positive cells recognized by specific mAbs (Novo Nordisk)
out of 500 cells counted, revealed by a FITC-conjugated goat
anti–mouse Ig antibody and observed by fluorescence micros-
copy.
 
Immunostaining Procedure.
 
Pancreas fragments (0.5 cm) were
snap frozen in isopentane, chilled at 
 
2
 
150
 
8
 
C and kept at 
 
2
 
80
 
8
 
C
until used. Serial cryostat pancreatic sections (5 
 
m
 
m) were allowed
to equilibrate to room temperature and exposed to absolute ace-
tone for 10 min before starting the alkaline phosphatase anti–alka-
line phosphatase (APAAP) complex procedure, or to a hydrogen
peroxide methanol solution for double staining (Dako Double
Stain Kit; Dako Corp., Santa Barbara, CA). Detection of antiglu-
cagon antibody (Dako Corp.) binding was accomplished using a
horseradish peroxidase–rabbit anti–horseradish peroxidase com-
plex (Dako Corp.) and revealed by 3,3
 
9
 
-diamino benzidine tet-
rahydrochloride. Bound anti-CD3 (Dako Corp.), anti-CD14
(Dako Corp.), anti–human perforin (provided by E.R. Podack,
University of Miami, Miami, FL), anti-CD95 (DX2, IgG1;
PharMingen), and anti-FasL (NOK-1, IgG1; PharMingen) mAbs
were detected with APAAP mouse (Dako Corp.) and revealed by
a Fast Red colorimetric substrate. Hematoxylin was used as a
counterstain. Control tissue sections were subjected to identical
treatment and analysis using irrelevant isotype-matched mAbs.
 
FasL Messenger RNA Analysis.
 
Total cytoplasmic RNA was
prepared from the NHP-purified islets, IDDM-purified islets, and
resting and PMA/ionomycin-activated PBLs from healthy indi-
viduals. The RNA was extracted using TRIZOL reagent
(GIBCO BRL, Gaithersburg, MD) according to the manufac-
turer’s instructions. For each preparation, 3 
 
m
 
g of total RNA was
reverse transcribed into a single-stranded cDNA (GeneAmp
RNA PCR Kit; Perkin-Elmer, Roche Molecular Systems, Inc.,
Branchburg, NJ).
 
In Situ Apoptosis Studies.
 
Pancreas cryostat sections (5 
 
m
 
m)
were mounted onto microscope slides and fixed with 4% parafor-
maldehyde. Permeabilization of the tissue was determined by in-
cubation with 0.1% Triton X-100, 0.1% sodium citrate (16). The
labeling of 3
 
9
 
-OH fragmented DNA ends (TdT-mediated
dUTP-X nick end labeling; TUNEL) was carried out by an in
situ apoptosis detection kit (In Situ Cell Death Detection, AP;
Boehringer Mannheim) following the instructions of the manu-
facturer. Detection of labeled ends was done with an antifluores-
cein antibody (Fab
 
9
 
2
 
 fragment) conjugated with alkaline phos-
phatase. 5-bromo-4-chloro-3-indolylphosphate (Dako Corp.) was
used as substrate. Sections were then counterstained with hema-
toxylin.
 
Results and Discussion
 
IL-1
 
b
 
 Induces Selective Fas Expression in 
 
b
 
 Cells.
 
To deter-
mine whether IL-1
 
b
 
 selectively induces Fas expression in 
 
b
 
cells but not in other pancreatic endocrine cells, normal
dispersed islet cells were treated 24 h with 50 U/ml IL-1
 
b
 
,
double stained with anti-insulin and anti-Fas mAbs, and
analyzed by flow cytometry. Fig. 1, 
 
A
 
 and 
 
B
 
 shows that
IL-1
 
b
 
–induced Fas expression in islet cells was restricted to
insulin-producing cells. The induction of Fas expression in
 
b
 
 cells peaked after 
 
z
 
24 h of IL-1
 
b
 
 stimulation, and was not
observed in any cell type after exposure to TNF-
 
a
 
 or IFN-
 
g
 
,
alone or in combination (Fig. 1, 
 
C and D). These data sug-
gest that some molecular component generated by IL-1b
stimulation may be responsible for Fas induction in b cells.
NO Induces Fas Expression in b Cells and Mediates IL-1b–
induced Fas Upregulation. NO is a reactive nitrogen interme-1195 Stassi et al.
diate with multiple biological effects (17). Different from
TNF-a or IFN-g, IL-1b is a potent inducer of iNOS in is-
let cells (11). To investigate the possible contribution of
NO in IL-1b–induced Fas expression, we treated normal
dispersed islet cells with IL-1b in the presence or absence
of the nitric oxide synthase inhibitor L-NMMA. Targeting
NOS activation by L-NMMA but not D-NMMA (18),
treatment inhibited IL-1b–induced Fas expression (Fig. 2,
A and B). Also, inhibition by L-NMMA was completely
reversed by excess of l-arginine, but not by d-arginine
(19), suggesting that NO generation is directly responsible
for IL-1b–induced Fas upregulation. To confirm this hy-
pothesis, we exposed islet cells to the NO donors SNP and
NOC-18 for 24 h and examined them for Fas expression.
Both SNP and NOC-18 were extremely effective in in-
ducing Fas expression in b cells (Fig. 2 A). As expected,
L-NMMA did not interfere with NO-induced (NOC-18)
Fas expression (Fig. 2 B). Taken together, these results sug-
gest a primary role for NO in sensitizing b cells to Fas-induced
apoptosis.
NO Primes Pancreatic b Cells for Fas-mediated Destruction.
To determine whether Fas is functional and able to induce
a death signal in b cells, we incubated IL-1b– or SNP–
treated and untreated islet cells with an agonist (CH-11) or
a blocking anti-Fas (ZB4) mAb and examined them for ev-
idence of apoptosis. Treatment with CH-11 mAb in the
absence of IL-1b or SNP did not trigger apoptosis. By con-
trast, incubation with CH-11 dramatically increased apop-
tosis in SNP– or IL-1b–treated-cells (Fig. 3 A). Immuno-
fluorescence staining and fluorescence microscopy analysis
revealed that after 24 h, essentially all cells surviving IL-1b
and anti-Fas treatment were glucagon-positive a cells,
whereas the recovery of insulin-producing cells was ex-
tremely low, indicating that only b cells underwent apop-
tosis (Fig. 3 B). Moreover, L-NMMA was able to com-
pletely suppress IL-1b–induced apoptotic cell death,
whereas the anti-Fas antagonist ZB4 did not interfere with
IL-1b– or SNP–induced apoptosis (Fig. 3 A). Thus, NO
mediates both Fas-independent and Fas-dependent b cell
apoptosis induced by IL-1b.
Fas Expression in Pancreatic b Cells During Insulitis. To in-
vestigate whether Fas is expressed in pancreatic b cells dur-
ing the insulitis process, we next analyzed expression and
distribution of Fas in endocrine and infiltrating cells in pan-
creatic specimens from newly diagnosed IDDM patients.
Immunohistochemical analysis of frozen pancreatic sections
from IDDM patients revealed that the few remaining insu-
lin-secreting b cells were strongly Fas positive, whereas the
b cells from NHP were negative (Fig. 4). The cellular infil-
trate in the diabetic pancreata was composed of a minor
population of CD14-positive cells with the morphology of
macrophages, and a number of CD3-positive lymphocytes
Figure 1. Fas expression in-
duced by IL-1b on enzymati-
cally dispersed NHP islet cells.
Control (A) or Fas (B) expression
on insulin-negative and -positive
islet cells exposed for 24 h to 50
U/ml IL-1b. (C) Fas expression
on b cells exposed for 24 h to
varying (i.e., ranging from 25 to
1,000 U/ml) doses of recombi-
nant IL-1b (closed squares), TNF-a
(open diamonds), IFN-g (closed di-
amonds), TNF-a plus IFN-g
(open squares), or tissue culture
medium alone (open circle). (D)
Time-course experiment (one
of eight performed on eight dif-
ferent human pancreata) demon-
strating Fas expression in b cells
incubated with IL-1b (50 U/
ml), TNF-a, IFN-g, and IFN-g
plus TNF-a (500 U/ml).1196 Nitric Oxide Primes Fas/FasL-mediated b Cell Apoptosis in IDDM
(Fig. 4). The majority of islet-infiltrating T cells were CD4
positive, whereas CD8-positive cells were occasionally ob-
served (14). All infiltrating T lymphocytes were perforin
negative (Fig. 4), suggesting that, at the time of our analy-
sis, perforin-mediated T lymphocyte cytotoxicity was not
playing a major role in the destruction of the pancreatic b
cells.
Detection of Apoptosis in Pancreatic b Cells Located in Prox-
imity to Reactive FasL1 T Lymphocytes Infiltrating the Diabetic
Pancreata. Fas requires the interaction with its ligand to
transduce the death signal. We therefore searched for FasL
expression in normal and IDDM pancreata. Different from
thyroid follicular cells (20), both the endocrine and the
exocrine cells from NHP were FasL negative, as were the
islet cells from IDDM patients (Fig. 5, A and B). However,
activated T cells infiltrating the islets were strongly FasL
positive (Fig. 5 A), as shown by the colocalization of FasL
and CD3 positivity in serial sections (Fig. 4 and 5 A).
Moreover, FasL transcripts were not detected in cDNA
prepared from purified islets of NHP, but were found in
cDNA preparations from diabetic pancreata (Fig. 5 B). Fi-
nally, TUNEL analysis of IDDM pancreas specimens
showed extensive apoptosis among Fas-positive b cells that
appears to proceed from the islet periphery (as shown in
Fig. 5 C) to encompass the entire islet (not shown), most
frequently in proximity to the CD3-positive cells produc-
ing FasL. b cells from NHP were consistently Fas negative
and showed no evidence of apoptosis. As expected, apop-
tosis in infiltrating T lymphocytes was also observed. This
Figure 2. Cytofluorometric analysis of enzymatically dispersed islet
cells from NHPs. (A) Insulin-positive cells were gated for subsequent
analyses. Untreated cells are Fas negative (control). Treatment with 50 U/
ml IL-1b or 0.5 mmol/liter SNP or 0.5 mg/ml NOC-18, induces Fas ex-
pression on gated insulin-positive cells. Exposure to 3 mmol/liter L-NMMA
suppresses IL-1b–induced Fas on b cells. Reactivity with irrelevant iso-
type-matched mAbs is shown in gray. (B) Mean values of two experi-
ments confirming results shown in A and demonstrating that exposure to
3 mmol/liter D-NMMA was not able to antagonize IL-1b–mediated Fas
expression on b cells. The addition of l-arginine (15 mM) overrode
L-NMMA inhibitory effect on IL-1b–induced Fas, whereas d-arginine
(15 mM) did not. Also, L-NMMA did not reverse NOC-18–promoted
Fas upregulation.
Figure 3. Induction of apoptosis in human pancreatic islet cells by anti-
Fas mAb (CH-11). (A) Islet cells incubated for 24 h in tissue culture me-
dium and then exposed for an additional 24 h to 200 ng/ml CH-11 mAb,
or in medium supplemented with IL-1b (50 U/ml) or 0.5 mmol/liter
SNP followed by control IgM, or in medium containing IL-1b or SNP
followed by 10 mg/ml ZB4 or CH-11 mAb, or in medium containing
IL-1b plus 3 mmol/liter L-NMMA followed by CH-11 mAb, were pro-
cessed for DNA content analysis by staining. Percentages of apoptotic
(i.e., hypodiploid) nuclei are indicated between shift markers, plotted on
log histograms as red fluorescence intensity (x-axis) versus relative nuclei
number (y-axis). (B) Evaluation of cell survival of human a (left) and b
cells (right) cultured in culture medium for 24 h and then for 24 h in me-
dium in the absence of IL-1b, in medium supplemented with IL-1b (50
U/ml; open squares), and control mAb (open circles), or in medium with IL-1b
and CH-11 mAb (closed circles), or in medium with IL-1b plus L-NMMA
and CH-11 mAb (closed triangles). Data shown represent the values at the
indicated time points of a representative experiment out of a total of seven
independent experiments performed.1197 Stassi et al.
Figure 4. Fas expression on human pancreatic islet cells from NHP and newly diagnosed IDDM patients. Double immunohistochemical analysis of
pancreas cryostat serial sections (top) exposed to anti-Fas mAb revealed by immunoenzymatic APAAP complex (red), and antiglucagon antibody revealed
by peroxidase-anti-peroxidase complex (brown), shows that Fas is specifically expressed on the non–glucagon-stained, insulin-producing b cells. CD3 and
CD14 expression (middle, red) on leukocyte subpopulations (arrows) present in pancreas cryostat sections from IDDM patients. Reactivity of pancreatic is-
lets from an IDDM patient (bottom left) and of the cellular infiltrate within the heart of a patient with myocarditis as a positive control (arrows, bottom right)
with an antiperforin antibody.1198 Nitric Oxide Primes Fas/FasL-mediated b Cell Apoptosis in IDDM
Figure 5. Detection of Fas ligand and apoptosis in vivo. (A) FasL expression on human pancreatic sections from NHP and from IDDM patients. (B)
Lane M, marker (100-bp DNA ladder; GIBCO BRL, Gaithersburg, MD). Two primers specific for the FasL coding sequence (59-CCA CCG CCA
CCA CTA CCA-39, nucleotides 212–229, and 59-TCT TCC CCT CCA TCA TCA CC-39, complementary to nucleotides 749–730; These sequence1199 Stassi et al.
may be the direct consequence of the autoregulated im-
mune process in which T cells, expressing both Fas and
FasL, are not only able to kill Fas positive target cells, but
also themselves or one another (21, 22).
Concluding Remarks. Fas-mediated cytotoxicity can be
induced by both CD4- and CD8-positive T cells, being
the major cytotoxic effector mechanism of CD4 cells (23,
24), which constitute the dominant subset of T cells infil-
trating the IDDM pancreata we have examined (14). Mul-
tiple islet antigens have been claimed as major targets of the
autoimmune aggression in IDDM, as both humoral and
cell-mediated autoimmune responses are polyclonal and
not  b cell specific (25). However, the selective expression
of Fas in b cells primed by NO may be responsible for their
specific killing as T cells expressing FasL may promote an
MHC unrestricted destruction of Fas-positive bystander b
cells, while sparing neighbor Fas-negative a and d cells. In
accordance with these results, it has been recently demon-
strated that transgenic NOD mice expressing FasL in b cells
show a higher rate of spontaneous diabetes and are more
sensitive to injection of diabetogenic T cells (9). By con-
trast, NODlpr/lpr mice, expressing a mutated Fas receptor,
are resistant to both spontaneous and T cell transferred dia-
betes, suggesting that Fas-induced b cell destruction medi-
ates both human and experimental autoimmune diabetes.
During the insulitis process, NO production is probably
not confined to IL-1b–primed b cells, as high levels of NO
could be released by several periinsulitis cell types, includ-
ing dendritic cells, macrophages, and endothelial cells (10,
26). The produced NO may directly induce apoptosis in b
cells, but NO-induced Fas expression may also mediate a
new mechanism of b cell destruction. The simultaneous
presence in IDDM pancreas of a number of apoptotic Fas-
positive b cells and infiltrating FasL-positive lymphocytes
suggests a major role for the aberrant Fas expression on
pancreatic b cells in the pathogenesis of human autoim-
mune diabetes.
data are available from EMBL/GenBank/DDBJ under accession number U11821) were selected to specifically amplify FasL cDNA prepared from: lane
1, PMA/ionomycin on activated T lymphocytes from PBLs; lane 2, nonactivated PBLs; lane 3, islets purified from NHP; and lane 4, islets purified from
IDDM patients’ pancreata. A 983-bp segment of the glyceraldehyde 3-phosphate dehydrogenase (G3PDH) gene (Clontech, Palo Alto, CA) was ampli-
fied from duplicate aliquots of the same cDNA preparations. (C) In situ TUNEL reaction revealed by 5-bromo-4-chloro-3-indolyl phosphate (black)
staining on IDDM and NHP pancreas sections prelabeled with anti-Fas or anti-insulin mAbs, using 3-amino-9-ethylcarbozole as a substrate (red). Arrows
indicate apoptotic nuclei among Fas- or insulin-positive cells.
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